Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Epigenomics AG (OJ:ECX) Epigenomics AG / Contract / Ad hoc: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG and Abbott Molecular Inc. Expand Strategic In Vitro Diagnostics Partnership Ad hoc announcement according to §15 WpHG processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Berlin, Germany, and Seattle, WA, USA, November 18, 2008 - Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A0BVT96) and Abbott Molecular Inc. (Abbott) today have expand their non-exclusive strategic partnership and amended their collaboration and license agreement in molecular diagnostics closed on September 25, 2007 accordingly.
Under the amended agreement Abbott obtains additional non-exclusive commercial licenses to Epigenomics' proprietary DNA methylation technology to develop and commercialize a blood test for colorectal cancer detection based on Epigenomics' biomarker Septin 9. Further, Abbott obtains access to blood samples collected in the ongoing PRESEPT clinical study sponsored by Epigenomics. The samples are to be used in the clinical validation of an Abbott Septin 9 IVD test product for regulatory approval in the U.S. In return, Epigenomics will receive a technology license fee, certain milestone payments and reimbursements in connection with the PRESEPT study and royalties on product sales.
Both companies jointly work with good progress and according to plan on the development of a Septin 9 IVD test product for Abbott's m2000 molecular diagnostics instrument and continue anticipating the launching of a CE-marked test in Europe in late 2009 followed by regulatory filing for U.S. approval in 2010.
The Septin 9 blood test for colorectal cancer detection is Epigenomics' leading product in development. With the PRESEPT clinical study, Epigenomics intends to demonstrate that blood testing for colorectal cancer with the Septin 9 biomarker fulfils the requirements of current U.S. guidelines for colorectal cancer screening and has the potential to provide health economic benefits.
End of ad hoc announcement
Further Information
For further information on Epigenomics AG please visit www.epigenomics.com. For Information on the PRESEPT clinical study please visit www.presept.net.
Contact
Epigenomics AG Dr. Achim Plum Sen. VP Corporate Development Kleine Praesidentenstr. 1 10178 Berlin Germany +49 30 24345 368 (phone) +49 30 24345 555 (fax) achim.plum@epigenomics.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
--- End of Message ---
Epigenomics AG Kleine Präsidentenstr.1 Berlin Germany
WKN: A0BVT9; ISIN: DE000A0BVT96; Index: CDAX, Prime All Share, TECH All Share; Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;
